Specialty code 183500000X · Roseville, CA
NPI
1346713849
Since 2019
Specialty
Specialty code 183500000X
Code 183500000X
Group practices
0
Medicare group memberships
Hospitals
0
Hospital affiliations
1600 Eureka Rd
Roseville, CA, 95661
Phone (916) 784-4217
Medicare paid
-
No Medicare services published
Medicare patients
-
Drug cost, 2024
$346K
2,825 prescriptions
Company payments
-
None reported
Medicare prescription drug claims, 2024
In 2024, the drug Nafisa Y Hassan prescribed most often to Medicare patients was Atorvastatin Calcium, with 394 prescriptions and refills. In total Nafisa Y Hassan wrote 2,825 Medicare prescriptions that cost $346K.
| Drug |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2019-01-07.
| Claims |
|---|
| 30-day fills |
|---|
| Patients |
|---|
| Cost |
|---|
| Atorvastatin Calcium Generic | 394 | 1,307 | 142 | $4,930 |
| Metformin Hcl Er Metformin Hcl | 292 | 971 | 119 | $3,002 |
| Glipizide Generic | 266 | 856 | 101 | $3,753 |
| Jardiance Empagliflozin | 197 | 612 | 75 | $114K |
| Metformin Hcl Generic | 166 | 550 | 64 | $2,196 |
| Ozempic Semaglutide | 129 | 132 | 23 | $95K |
| Humulin N Insulin Nph Human Isophane | 116 | 343 | 52 | $19K |
| Lisinopril Generic | 113 | 374 | 44 | $1,364 |
| Veo Insulin Syringe Syringe-Needle,insulin,0.5 Ml | 109 | 330 | 46 | $2,570 |
| Losartan Potassium Generic | 99 | 306 | 34 | $1,361 |
| Amlodipine Besylate Generic | 97 | 319 | 35 | $1,163 |
| Insulin Glargine-Yfgn Generic | 91 | 254 | 43 | $11K |
| Simvastatin Generic | 76 | 230 | 26 | $1,062 |
| Rosuvastatin Calcium Generic | 73 | 243 | 25 | $852 |
| Glimepiride Generic | 68 | 224 | 26 | $1,196 |
Brand drugs: 754 claims; generic drugs: 1,879 claims.
Money and other things of value reported by the companies
No payments from drug or medical device companies to Nafisa Y Hassan were reported in the years we have.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.